contract dose manufacturing industry by the numbersadv.pharmsource.com/articles/article7832.pdf ·...
TRANSCRIPT
Contract Dose Manufacturing Industry by the Numbers
Composition, Size, Market Shares, Profitability and Outlook
2013 edition
Related Market Intelligence Briefings and In-depth Analyses from PharmSource
2012 NDA Review: CMOs Tread Water (April 2013)
Are CMOs Losing the Make-versus-Buy Battle? (June 2012)
Demand and Supply for Contract Manufacturing
of Injectable Drugs - 2013 Edition (Coming Q4 2013)
©PharmSource 2013
PharmSource
9870 Main Street
Fairfax, VA 22031
703-383-4903
www.pharmource.com
1
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
Letter from the President
PharmSource is pleased to present the 2013 edition of our report Contract Dose Manufacturing
Industry by the Numbers: Composition, Size, Market Shares, Profitability and Outlook.
This is the third year we have published the report, and as in past years we put our emphasis on
presenting a quantitative portrait of the dose manufacturing industry that provides unique strategic
insight.
PharmSource is the acknowledged authority on the contract dose manufacturing industry. Thanks
to our ongoing program of industry research and analysis, we are confident that Contract Dose
Manufacturing Industry by the Numbers is the most authoritative and reliable portrait of the
contract dose manufacturing industry available to the bio/pharmaceutical industry.
■■ It is founded on the industry’s most comprehensive and detailed database of the dose CMO
industry, the PharmSource Strategic Advantage Database of Contract Services.
■■ It is driven by our unique model of the dose manufacturing industry which we continuously
update and refine.
■■ The model and assumptions are fully explained so readers can understand how the analysis
and conclusions were arrived at.
CMOs will find this report an indispensable resource for understanding their industry and a
critical input in their strategic planning efforts.
Sourcing professionals in bio/pharmaceutical companies will find the report a valuable resource
for understanding a critical component of their supply base that will provide insights for supplier
selection and management.
I would like to acknowledge the contributions of several colleagues to this report;
■■ Saul Richmond, PhD, Director of Market Intelligence, PharmSource
■■ Lisa Hinkle, Managing Editor, PharmSource
■■ Judy Ludwin Miller, Vice President, PharmSource
■■ Andrew Badrot, CEO, CMS Pharma
■■ Sue Gift, SG Graphics
2
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
If you have comments or questions regarding the report, please contact me directly.
Thank you for your purchase of this report and your interest in PharmSource.
Sincerely,
Jim Miller, President
i
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
Table of Contents
Letter from the President .................................................................................................. 1
Table of Contents ..............................................................................................................i
Chapter 1: Executive Summary ...................................................................................... 2
Chapter 2: Industry Composition and Size ..................................................................... 4
Chapter 3: CMO Market Shares .................................................................................... 9
Chapter 4: CMO Profitability ...................................................................................... 14
Chapter 5: What it Means ............................................................................................ 16
Appendix 1: Methodology for Market Size and Growth Estimates ................................... 20
Appendix 2: Companies included in the CMO Universe .................................................. 25
2
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
Executive Summary
1.1 This report characterizes the contract dose manufacturing industry along a number of
quantitative dimensions, including number and type of participants, market size, market
shares of the top CMOs and profitability. We also assess the outlook for the industry.
1.2 The contract dose manufacturing universe, for purposes of this report, includes companies
that actively promote themselves as contract manufacturers (CMOs) that produce a client’s
formulation for pharmaceuticals supplied to the highly regulated markets in North America,
Europe and Japan.
1.3 The contract dose manufacturing universe includes 195 companies headquartered
primarily in North America, Europe, Japan and India. Nearly 70% of those companies
pursue contract manufacturing as their primary business, while the others contract manu-
facture in facilities where they produce their own products.
1.4 Of the 195 CMOs, only 37 can be considered global companies in the sense that they have
manufacturing and/or business development activities across multiple regions. Most CMOs
focus on serving their immediate regional market.
1.5 The size of the dose CMO market in 2012 was $14.7 billion, a 7.0% increase from 2011.
Organic growth, i.e., without the impact of acquisitions of facilities from bio/pharmaceu-
tical companies, was 6.6%.
1.6 Standard dose products, including solid dose, semisolid and non-injectable liquids,
accounted for 52% of the market in 2012. Injectables accounted for 31% and specialty dose
forms, including softgels, transdermal and blow-fill-seal, accounted for 17%.
1.7 The 32 CMOs with revenues of $100 million or more accounted for 68% of dose CMO
industry revenues. By contrast, the 140 CMOs with revenues under $50 million accounted
for just 19% of industry revenues.
1.8 The average EBITDA margin for CMOs for which profitability data is available was 12%;
by contrast, the typical large bio/pharmaceutical company has an EBITDA margin of 35%.
Larger CMOs appear to have better margins than smaller CMOs.
Chapter 1
3
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
1.9 The prospects for organic growth for dose CMOs are limited by intense competition, inability
to control product volumes and declining prices for their clients’ products. Major CMOs will
seek growth by acquiring other CMOs and by diversification into their own generic and OTC
products.
4
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
Industry Composition and Size
2.1 This chapter describes the principal characteristics of the dose CMO universe. We define
the universe, analyze its composition and estimate the market size and growth.
DEFINITION OF THE DOSE CMO UNIVERSE
2.2 For purposes of this analysis, the CMO universe includes companies with the following
characteristics:
a. They manufacture a client’s formulation for pharmaceuticals supplied to the highly
regulated markets in North America, Europe and Japan.
b. They actively promote themselves as contract manufacturers and seek contract manu-
facturing relationships, as evidenced by website, trade magazine ads and participation
in trade shows.
c. Their contract manufacturing activities are not primarily part of a product or tech-
nology licensing agreement or a business relationship other than what is typical of a
third-party manufacturing relationship.
2.3 This definition excludes a number of manufacturers that other analysts might include as
part of the CMO universe:
a. Companies that engage solely in private label manufacturing, i.e., manufacturers who
only develop and manufacture formulations that are sold as another company’s brand.
These arrangements are quite common in the OTC and generics markets. Note: Many
OTC and generics manufacturers participate in both the contract manufacturing and
private label businesses.
b. Companies that manufacture only nutritional supplements or health and beauty
products.
c. Manufacturers that serve only emerging markets.
d. Manufacturers supplying only products formulated using a technology that is patented
by and available solely to the manufacturer. For instance, Alkermes generates most of
Chapter 2
5
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
its revenues from manufacturing out-licensed products that incorporate its proprietary
drug delivery technology (although it does have some conventional CMO business, as
well).
e. Manufacturers supplying products whose rights they have sold to another company.
For instance, UCB reported contract manufacturing revenues of nearly $100 million
for 2012, but most of that revenue came from manufacture of products that UCB sold to
GlaxoSmithKline in 2009.
f. Manufacturers supplying products to former corporate parents or affiliates following a
divestiture or spin-off. Examples include Abbvie and Abbott’s manufacturing relation-
ships with each other, and Pfizer’s manufacturing relationship with Zoetis.
2.4 Readers should note that, while we try to hew as closely as possible to this definition, as a
practical matter, we are unable to extract all non-conforming activities from the reported
or estimated revenues of individual companies in the CMO universe. We feel confident that
any resulting over- or understatement of market size will be well within the margin of error
for an undertaking such as this that requires a significant amount of estimation.
INDUSTRY DEMOGRAPHICS
2.5 According to the PharmSource Strategic Advantage Database of Contract Service
Providers, 195 dose CMOs meet the criteria described above. Those 195 companies can be
characterized along a number of dimensions.
2.6 The first dimension is what role contract manufacturing plays in a company’s overall busi-
ness portfolio.
a. 135 (69%) are dedicated CMOs, while 60 (31%) operate within companies whose
primary business is manufacturing and marketing proprietary products.
b. 154 (79%) pursue contract dose manufacturing as a strategic business opportunity,
rather than just an opportunity to absorb excess manufacturing capacity. This includes
19 of the companies whose primary business is proprietary products. Those 19 devote
considerable business development and project management resources to their CMO
business.
6
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
2.7 A second dimension is the stage
that the company plays on.
a. 37 CMOs (19%) are consid-
ered to be global because
they have manufacturing
facilities across multiple
regions or have significant
business development
operations outside their
home territory. The 158
(81%) regionally focused
CMOs include:
i. 94 in Europe;
ii. 50 In North America;
iii. 12 in Japan; and
iv. Two in other regions.
b. A substantial majority of CMOs have facilities in Europe.
i. 122 (63%) have facilities in Europe.
ii. 72 (37%) have facilities in North America.
iii. 14 (7%) have facilities in Japan.
iv. 13 (7%) have facilities in the rest of the world.
2.8 139 (71%) offer services in just one dose category, while 56 (29%) offer services in multiple
dose categories.
i. 144 (74%) offer standard dose (solid, semisolid and liquid dose forms);
ii. 82 (42%) offer injectables; and
iii. 33 (17%) offer specialty dose forms (softgel, transdermal, inhalation,
blow-fill-seal).
Figure 2.1 Geographic Reach of Dose CMO Universe
Regional-NA;50
Regional-Japan;12
Regional-EU;94
Regional-ROW; 2
Global; 37
Source: PharmSource Dose CMO model
7
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
2.9 There are 32 CMOs with
revenues in excess of $ 100
million; they represent 16% of
all the CMOs in our universe.
The majority of dose CMOs are
small, with revenues less than
$25 million (Figure 2.2).
INDUSTRY SIZE AND GROWTH
2.10 PharmSource estimates the size
of the dose CMO market in 2012
to have been $14.7 billion. That
represents a 7.0% growth rate
over the $13.7 billion we esti-
mated for 2011.
2.11 Of the $1 billion in incremental industry revenue, PharmSource estimates that about $100
million was inorganic, i.e., it arose from acquisitions of facilities from bio/pharmaceutical
companies during the 2011-2012 period. The major acquisition events impacting the growth
estimate are listed in Table 3.2.
Figure 2.3 Dose CMO Market Size
0.0%
1.0%
2.0%
3.0%
4.0%
5.0%
6.0%
7.0%
8.0%
$-
$2.0
$4.0
$6.0
$8.0
$10.0
$12.0
$14.0
$16.0
2009 2010 2011 2012
Grow
th Rate M
arke
t Siz
e -$
bill
ion
Market Size Growth Rate
Source: PharmSource Dose CMO model
Fig. 2.2 Distribution of Dose CMOs by Revenues (Number of CMOs)
$500+ M; 5 $250-499 M; 8
$100-249 M; 20
$50-99 M;27
$25-50 M;42
$<25 M; 92
Source: PharmSource Dose CMO model
8
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
2.12 The $900 million in organic growth translates to a growth rate of 6.6%. This is the net
incremental CMO revenue resulting from new products or higher volumes of existing
products.
2.13 Standard dose products, which include conventional solid, semisolid and non-injectable
liquid products, account for 52% of the CMO market, while injectables account for about
31% (Figure 2.4). Specialty products account for 17%; these include softgel, transdermal, and
inhalation products, plus products manufactured using the blow-fill-seal process.
2.14 CMO revenues are reflected as Cost of Goods Sold on the books of their clients, so
comparing CMO revenues to cost of goods for all bio/pharmaceutical sales is an indicator
of contract dose manufacturing’s penetration into the industry. PharmSource estimates that
dose CMOs account for about 22% of the bio/pharmaceutical industry’s dosage form cost of
goods.
Figure 2.4 Dose CMO Dosage Form Segments ($ billion)
Specialty;$2.5
Injectable;$4.5
Solid/Liquid/
Semisolid;$7.7
Source: PharmSource dose CMO model
9
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
CMO Market Shares
3.1 This chapter describes the distribution of
market share within the dose CMO industry
and analyzes the characteristics of the market
share leaders.
LARGEST CMOS
3.2 There are 32 CMOs with revenues of $100
million or more. Those 32 CMOs account for
68% of dose CMO industry revenues, though
they represent just 16% of all CMOs (Figure
3.1). By contrast, CMOs with revenues under
$50 million account for 70% of all CMOs, but
just 19% of industry revenues.
3.3 Our list of CMOs with revenues of $100 million or more has changed somewhat from last
year’s (Table 3.1):
a. Aenova moved into the $500+ million category following its acquisition of Temmler.
That acquisition did not take full effect until January 2013, but we are showing them as
a single entity.
b. Patheon’s revenue now includes the contract manufacturing revenues of Banner
PharmaCaps, even though that deal was not fully consummated until January 2013.
Patheon was already in the $500+ million category.
c. DPT Laboratories moved into the $250-499 million category.
d. Fertin Pharma, a Denmark-based manufacturer of pharmaceutical chewing gum prod-
ucts, and Rottendorf Pharma, a Germany-based CMO of solid dose products, were added
to the list.
e. Taiyo Pharma, a Japanese generics company that had been active in contract manufac-
turing, was removed from the list. Teva has acquired this company, and we believe it
no longer actively seeks contract manufacturing projects.
Chapter 3
Figure 3.1 Dose CMO Industry Market Shares by Company Size
$500+ M
$250-499 M
$100-249 M
$50-99 M
$25-49 M
$<25 M
Source: PharmSource dose CMO model
10
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
Table 3.1 Dose CMOs with Contract Manufacturing Revenues of $100 million or More
Revenue Range
($ million)Company
Solid/Semisolid/
LiquidInjectable Specialty
CommercialManufacturing
Locations
$500 + Aenova w/Temmler X Softgel NA, EU
Baxter X NA, EU
Catalent X X Softgel, Blow-Fill-Seal
NA, EU, SA, AUS, Japan
Famar X X EU
Fareva X X NA, EU
Patheon w/Banner X X Softgel NA, EU
$250-499 Corden X X EU
DPT X NA
Haupt X X EU
Hospira X NA, EU, AUS
LTS Lohmann Transdermal, Oral Films NA, EU
Nipro Pharma X X Japan
Recipharm X X EU
Vetter X EU
$100-249 Abbvie X NA, EU, SA, Asia, Japan
Aesica X X EU
Boehringer-Ingelheim X X NA, EU, SA, Asia
Bushu X Japan
Cenexi X X EU
CMIC X NA, Japan
Delpharm X X EU
DSM X X NA
Fertin Pharma X EU
Jubilant HollisterStier X X NA
Kemwell X X EU, India
Klocke X EU
Nextpharma X EU
Rottendorf X EU
Sanofi X EU
Synerlab X EU
Takeda X X NA, EU, SA
Unither Blow-Fill-Seal EU
Source: PharmSource dose CMO model
11
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
3.4 Aside from the two major acquisitions of one CMO by another, facility acquisitions
re-shaped the industry to some degree in 2012 (Table 3.2).
a. There were three facility acquisitions by CMOs. Two of these involved a CMO
acquiring a facility from a biopharma company, resulting in a net increase in CMO
industry capacity.
b. The other deal in 2012 involved a CMO, Cenexi, acquiring an injectables facility in
Belgium that another CMO, Nextpharma, had placed into bankruptcy proceedings.
That was the second time Cenexi had acquired a CMO facility out of bankruptcy; in
2011 it acquired Osny Pharma (Osny, France). Osny was once a Catalent facility.
Table 3.2 Significant CMO Facility Acquisitions in 2012
Company Date Facility Impact
Fareva December 2011 Sigmar (Italy) $21 million, but includes cosmetics and nutritional products. 2012 is first full year.
August 2011 Richmond, VA Acquired from Pfizer in 2011. 2012 is first full year.
Delpharm May 2012 Gaillard, France Acquired from Bayer, revenue unknown.
January 2012 Drogenbos, Belgium
Acquired from Laboratoire Besins, revenue unknown. 2012 is first full year.
June 2011 Huninge, France
Acquired from Novartis, revenue impact unknown. 2012 is first full year.
Cenexi January 2012 Braine d’Alleud, Belgium
Acquired out of bankruptcy from Nextpharma; revenues were $30 million in 2011. 2012 is first full year.
July 2011 Osny, France Acquired out of bankruptcy; revenues of $15 million in 2010, $30 million in 2009. 2012 is first full year.
Aenova August 2011 Lyon, France Leasing site from Skyepharma and continuing to make products manufactured there. 2012 is first full year.
Source: PharmSource Strategic Advantage Database
CHARACTERISTICS OF LARGEST CMOS
3.5 As might be expected, the 32 largest dose CMOs have different characteristics from the rest
of the CMO universe.
a. All but one approach the CMO business as a strategic opportunity, rather than just an
opportunity to absorb unused manufacturing capacity; that judgment is based on the
way they promote the business and their infrastructure to support it. By comparison,
76% of the smaller CMOs approach contract manufacturing as a strategic opportunity,
12
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
while 24% view it as an absorber
of excess capacity.
b. 48% of the largest dose CMOs
participate in more than one
dose form category, while just
29% of smaller CMOs offer
more than one dose category.
c. 52% of the largest CMOs
compete on a global level versus
just 12% of the smaller CMOs.
The modest share of CMOs that
can be considered global reflects
the 12 CMOs with revenues of
$100+ million that are focused
primarily on the European
market, and the three that are focused on the Japanese market. While those CMOs
may have a few approvals in North America, their operations and business develop-
ment efforts are focused in their home regions.
3.6 The 13 very largest CMOs (Figure 3.2), i.e., those with revenues of $250 million or more,
exhibit characteristics that one might expect of market share leaders.
a. All approach the contract manufacturing business as a strategic business opportunity
even though two are part of organizations with very large proprietary products
businesses.
b. Nine offer manufacturing capabilities in at least two dose form categories. Four focus
on a single dosage form.
c. Nine (69%) can be considered to compete on a global basis. Three compete primarily in
Europe and one in Japan.
d. Acquisitions have played an important role in the growth of the 13 largest dose CMOs:
Figure 3.2 Market Shares of Largest Dose CMOs
Source: PharmSource dose CMO model
Baxter
Catalent Famar
Fareva
Patheon
Aenova
Corden Pharma
Haupt Hospira
LTS Lohmann
Nipro Pharma Recipharm
Vetter
180 others
13
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
i. Six have acquired facilities from bio/pharmaceutical companies in the past five
years; and
ii. Three have acquired other CMOs in the past five years.
e. Most of the 13 largest CMOs have enjoyed modest growth: just 3.3% in 2012, 5.5% p.a.
average for the two years 2011-2012, and 6% p.a. for 2009-2012. These are slightly
below the overall industry growth rates for the period. CMOs with revenues of $100-
249 million were more likely to have above-average growth rates.
14
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
CMO Profitability
4.1 Analysis of CMO profitability faces a number of practical limitations.
a. Most CMOs do not report their financial results publicly, and those that do may only
report revenues, and not profitability. Private companies operating in many European
countries are required to file financial statements with government registries, but this
is not the case for companies in the US and Canada.
b. It may not be possible to gauge the profitability of the CMO business separate from
other activities the company engages in.
c. Accounting rules and terminology differ from country to country.
4.2 Accepting these limitations, we have been able to develop profitability measures for 23 of
the companies in our CMO universe. We are using as earnings before interest, tax, depre-
ciation and amortization (EBITDA) as our measure of profitability.
4.3 Our analysis showed that the average EBITDA margin for the 23 CMOs in 2011 was 12%.
Four CMOs had margins in excess of 20%, while 11 had margins below 10%.
4.4 There is definitely some correlation between CMO size and profitability (Figure 4.1). The
five CMOs with revenues in excess of $250 million had the highest margin. Mid-size CMOs
($100-250 million)
had the lowest
margins, while the
smaller CMOs were
somewhat below the
average.
4.5 CMOs manufac-
turing specialty
dose forms, such as
transdermal products
and cytotoxics, also
tend to have higher
margins.
Chapter 4
Figure 4.1 CMO Profit Margins by Company Size
0%
2%
4%
6%
8%
10%
12%
14%
16%
18%
$250+ M $100-249 M $50-100 M $<50 M
EBIT
DA
Mar
gin
CMO Revenues
Source: PharmSource research in public sources
15
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
4.6 To provide some context for these CMO margins, it should be noted that the average
EBITDA margin for the global bio/pharmaceutical companies (the 25 largest bio/pharma-
ceutical companies) is 35%, i.e., almost three times greater than the CMO margins.
16
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
What it Means
5.1 In this chapter, we provide further analysis of the preceding characterization of the dose
CMO industry and assess the implications.
THE CMO INDUSTRY ISN’T SO FRAGMENTED AFTER ALL.
5.2 Because of the large number of mostly undifferentiated participants, the dose CMO
industry gives the impression of being highly fragmented. Our analysis, however, indicates
that the industry is, in fact, significantly consolidated. The 15 largest CMOs (8% of the 195
dose CMOs) together claim nearly 50% of the market, and the 32 largest (16%) 68%.
5.3 The degree of consolidation varies among dose forms. For injectables, the five largest CMOs
have a 44% market share, but for the standard dose forms, the top five account for just 29%.
Market share among the specialty dose manufacturers has to be further broken down by the
specific dose; there, we see clear domination by individual CMOs, including Catalent for
softgels and LTS Lohmann Therapie Systems for transdermal patches.
5.4 Industry organic growth and taking market share from rivals don’t appear to have been
major factors in consolidating the industry. Only eight of the 32 largest CMOs had growth
rates in excess of 10% in 2012, and only two of those achieved that growth organically.
Rather, the main factors in consolidation have been:
a. Acquisitions of one CMO by another CMO. These include Aenova’s acquisition of
Temmler, Patheon’s acquisition of Banner PharmaCaps and Cenexi’s acquisition of
Nextpharma’s sterile operations in Belgium, all in 2012.
b. Acquisitions of redundant facilities from global bio/pharma companies. Fareva,
Recipharm, Aesica, Delpharm and Corden have all built themselves up in recent
years by acquiring facilities from bio/pharma companies. These deals simultaneously
increase the size of the industry and the acquirer’s market share.
5.5 The difficulty of achieving substantial organic growth is not surprising, given the nature of the
CMO industry. Once a CMO has won a contract to manufacture a product, the future is out of
its hands; it can’t determine the regulatory or commercial prospects of the product. A business
strategy geared to driving organic growth would seem to require one of two elements:
Chapter 5
17
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
a. Signing a large enough share of available contracts to build a large and diversified
portfolio that can drive growth. Given the mostly commodity nature of dose manufac-
turing, this would probably be a price-driven strategy that would sacrifice margin for
volume. Most CMOs cannot afford to compete on a price basis for a sustained period
and still be able to make the necessary investments and return on investment.
b. Create a well-differentiated offering that allows it to command a premium price in an
otherwise-commoditized market, either by offering a niche dose form or truly superior
performance. This has been done successfully in a few cases, e.g., Vetter in injectables
manufacturing and Lohmann for transdermal patches. However, it is not clear that
the market will pay a significant premium for performance on a broad-enough basis to
make this a broadly applicable strategy.
5.6 To the degree that there is a fragmentation problem in the dose CMO industry, it is centered
primarily in Europe, which is overpopulated with CMOs. According to IMS Health, bio/
pharmaceutical industry revenues in Europe are only two-thirds the size of industry
revenues in North America, yet 63% of CMOs in our universe have facilities there. Europe
is especially overloaded with small CMOs: 50 with revenues under $25 million versus 30 in
North America.
5.7 The CMO overpopulation problem in Europe reflects two major factors. For one, since
Europe is not one country, but many, with different governments, languages and cultures, it
offers opportunities for small, indigenous companies serving local markets. That is unlikely
to change in the foreseeable future. Further, labor and other regulations make it expensive
to close manufacturing operations in Europe and encourage companies to offload redun-
dant facilities to CMOs.
5.8 The European financial crisis has resulted in significant cuts to drug prices, compounding
the price pressures on CMOs caused by too much manufacturing capacity. Despite the
obvious need for structural economic reforms, few seem to be forthcoming, and the road-
blocks to closing facilities remain. Continued low margins will mean that companies cannot
invest to maintain capacity, and may be forced to find operating savings in ways that make
them vulnerable to quality problems. European CMOs could find a backdoor out of the
business due to compliance problems or bankruptcy filings.
18
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
WHAT ARE THE GROWTH PROSPECTS FOR DOSE CMOS?
5.9 The dose CMO industry has achieved modest growth in recent years (6-7% organic growth
in the past two years), but most of the largest CMOs have been only in the 4-5% range. That
kind of growth, coupled with the marginal profitability of the CMO business, isn’t likely to
satisfy the owners of the largest CMOs, most of which are private equity firms with aggres-
sive financial targets and defined holding periods. Looking for more rapid and profitable
growth is a primary strategic challenge for most CMOs.
5.10 As we noted above, organic growth is not likely to be a growth avenue for most CMOs; it’s
just too difficult. While the low penetration (22% on a cost of goods basis) for contract dose
manufacturing would suggest that there is considerable room for expansion, there is not
much evidence to suggest that bio/pharmaceutical companies are inclined to give CMOs a
greater share of their dose manufacturing in the near term.
a. Dose CMOs’ share of new drug approvals has been stagnant for the past five years or
more. As PharmSource has demonstrated in our Market Intelligence Briefing, 2012
NDA Review: CMOs Tread Water, the share of new NDA approvals being manufac-
tured by dose CMOs has averaged 40% since 2005, with little variance around that
average. The two areas of greatest anticipated industry growth, biologics and generics,
show the lowest levels of outsourcing.
b. In fact, most global bio/pharmaceutical companies continue to invest in new plants
and equipment, especially API and dose facilities for manufacturing biologics (see
PharmSource Market Intelligence Briefing, Are CMOs Losing the Make-versus-Buy
Battle?).
5.11 Organic growth will also be hampered by the difficult pricing environment for CMOs.
Pricing faces difficult headwinds from two factors: the downward pressure on drug prices
resulting from government budget cutting and generic competition; and the overcapacity
problem throughout much of the CMO industry, but especially in Europe.
5.12 With organic growth not likely to be a major growth driver, CMOs are left with two other
options: acquisitions and diversification.
a. Facility acquisitions, which fueled industry growth for much of the last decade, are
less likely to be a significant growth vehicle. CMOs have learned that whatever
19
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
their short-term attraction, many of those facilities ended up being albatrosses of
under-utilization, high operating costs and under-investment. Where these deals will
continue, it will most likely be where they allow the acquiring CMO to enter a new
market or significant dose form. A prime example is Fareva’s acquisition of the Pfizer
OTC facility in Richmond, VA, that allowed Fareva to get a foothold in the US market.
b. Acquisitions of one CMO by another CMO could increase, driven by the objective
of gaining economies of scale or adding attractive new dosage forms to a portfolio.
Aenova’s acquisition of Temmler would seem to be a play for economies of scale, while
Patheon’s acquisition of Banner PharmaCaps was, in part, an opportunity to acquire
significant softgel capability. We may also see contract API manufacturers acquire
dose CMOs in order to build a one-stop manufacturing offering; that appears to be the
rationale behind Siegfried’s acquisition of Alliance Medical Products (AMP) in 2012.
5.13 For diversification, more CMOs are turning to proprietary products, especially generic and
OTC products. Proprietary products generally have higher margins than contract manufac-
tured products, and give the CMO greater control over its volumes and capacity planning.
OTC and generic products are attractive because they carry little or no R&D risk, and offer
private label opportunities that require little sales and marketing expense.
5.14 Recent examples of CMOs moving into proprietary products abound. Patheon’s acquisition
of Banner PharmaCaps was driven, in part, by the opportunity to leverage Banner’s propri-
etary products portfolio and know-how. Haupt Pharma recently got its first ANDA approval
in the US. DPT Laboratories will act as the captive manufacturer for its new parent
Renaissance Pharma, a private equity-backed specialty pharmaceutical company. Other
large CMOs, like Baxter and Hospira, have built large and successful CMO businesses by
sharing capacity between proprietary products and contract manufacturing.
20
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
Methodology for Market Size and Growth Estimates
A.1 PharmSource’s estimates of the dose CMO market size and market shares are generated
by our proprietary contract dose manufacturing model, which determines the market size
based on the revenues of CMOs listed in our PharmSource Strategic Advantage database.
A.2 PharmSource Strategic Advantage database is a comprehensive database of contract manu-
facturers and CMC development services providers.
a. It includes detailed profiles on more than 340 dose CMOs and 550 dose manufacturing
sites in North and South America, Europe, Asia, Africa and Australia.
b. Each profile includes:
i. Detailed capability information;
ii. Products manufactured by the CMO;
iii. Known clients;
iv. Mergers, acquisitions and alliances;
v. Financial information (where available); and
vi. Key executives and contacts.
A.3 To determine a company’s contract manufacturing revenues we use publicly available
records wherever possible.
a. For public companies, we use regulatory filings, investor presentations and disclosures
on company websites.
b. Many privately owned companies reveal their revenues on their websites or in media
interviews. For privately owned CMOs based in the UK, Ireland, Germany, France
and Italy, we have used financial data that private companies must report to official
corporate registries. While these reports are publicly available, usually for a fee, we
cannot republish the individual company information.
Appendix 1
21
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
A.4 When publicly reported revenues are not available, we use various estimation techniques.
a. Where the number of employees is reported, we estimate revenues by multiplying the
number of employees by an estimated revenue per employee (usually $150,000- 200,000
per employee).
b. Where there are historical numbers, we extrapolate from those numbers based on other
reports regarding such factors as growth and new capabilities and capacity.
c. We talk regularly with industry participants and have a sense of their size and growth
from those conversations.
d. Where other data are not available, we have categorized companies into size ranges
and use the midpoint of those ranges to estimate the revenue for companies in that
category.
A.5 All revenues are converted to US dollars. We keep the exchange rate value constant from
year to year in order in order to capture real changes in company revenue and reduce the
effects of currency fluctuations.
A.6 For a few companies that are known to have a significant level of Phase1/2 development
offerings in their service mix, we have reduced the reported revenue number based on our
informed estimate of the share of total revenues that are from development activities. We
count manufacture of Phase 3 clinical trial supplies as part of commercial manufacturing
revenues.
A.7 We have had to use estimates for a number of companies that manufacture multiple dose
forms but do not report revenues separately by each dose form.
A.8 While there is a likelihood of error in any estimate for any single company, we are confident
that estimation errors will largely cancel each other out and our reported numbers are a
reasonable representation of the dose manufacturing market. The greatest chance of error
is with the smaller companies (less than $50 million), but as these companies represent less
than a quarter of total industry revenues, any net error resulting from estimates for these
companies will be small.
22
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
CMO CLASSIFICATIONS.
A.9 To provide further insight on the nature and structure of the dose CMO industry, we have
characterized the participants along several strategic and operational dimensions in addi-
tion to revenues.
a. Principal business:
i. “Dedicated CMOs” are companies whose manufacturing assets are used
primarily for manufacturing of client products.
ii. “Proprietary products CMOs” are companies that manufacture and market
proprietary products and/or technologies that comprise the bulk of their revenues.
At proprietary products CMOs, client products share capacity used to manufac-
ture proprietary products.
iii. Note: For a company whose primary business is manufacturing proprietary prod-
ucts, the CMO business can still be considered strategic e.g., Hospira One2One or
Baxter Biopharma Solutions.
b. Degree of focus on contract manufacturing:
i. “Strategic CMOs” are companies for which contract manufacturing is a core busi-
ness activity, as evidenced by:
1. Contract manufacturing represents a significant share of company’s revenue
and profit.
2. The company maintains dedicated sales and marketing and project manage-
ment infrastructure to support the contract manufacturing business.
3. The company will make capital investments specifically to support the
contract manufacturing business.
4. The company will entertain a broad range of projects, including those that
might require special capital investment.
5. Note: “Strategic” can include dedicated CMOs and companies that share
capacity used for proprietary products to support contract manufacturing.
23
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
ii. “Opportunistic CMOs” pursue contract manufacturing primarily as a means of
absorbing unused manufacturing capacity.
6. Contract manufacturing represents a small amount of company’s total
revenue.
iii. The company is highly selective in accepting contract manufacturing projects, and
will only accept projects that fit into available capacity.
7. Opportunistic CMOs usually favor tech transfer projects over NDA projects.
c. Dose form offering:
i. “Single dose form CMOs” manufacture products in only one of the three major
dose categories we have identified:
8. Standard (solid, semisolid, oral and topical liquids);
9. Injectable; or
10. Specialty (softgel, blow-fill-seal, transdermal, inhalation).
ii. “Multiple dose form CMOs” manufacture products in two or more of these
categories.
d. Geographic reach:
i. “Global CMOs” have manufacturing assets and/or a substantial business develop-
ment presence across multiple geographic regions. They have regulatory approvals
from all of the major western regulatory agencies (FDA, EMA, MHRA, etc.).
ii. “Regional CMOs” have all of their manufacturing assets in a single geographic
region, confine most of their business development efforts to that region, and
ship most of their production to clients within that region. They may have a few
approvals outside of their home region, but their focus is regional.
INDUSTRY COST OF GOODS.
A.10 To measure the contract dose CMO industry’s penetration of the total market opportunity,
in paragraph 2.14 we stated that the dose CMO industry revnues accounted for 22% of the
24
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
bio/pharmaceutical industry’s total dosage form cost of goods. We calculated industry dose
cost of goods as follows:
a. We started with IMSHealth’s estimate of bio/pharmaceutical industry revenues in
North America, Europe and Japan of $765 billion.
b. We assume a dose cost of goods of about 8% of revenues. Total cost of goods in the
industry, including API, dose and logistics, generally runs 15-20% for branded products
and 40% for generic products; the 8% is a blended estimate of the share of cost of goods
going to the dosage form.
25
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
Companies included in the CMO Universe
Appendix 2
3M Drug Delivery Systems
Abbott Contract Manufacturing
Abbvie Contract Manufacturing
Accucaps
Accupac
Aenova
Aesica
Akiyama Jyozai
Akorn
AMRI
Alcala Farma
Alfa Wasserman
Alkermes
Allergy Laboratories
Alliance Medical Products
Almac
Althea Technologies
Applied Laboratories
Aseptic Technologies
ASM Aerosol-Service AG
Aspen Bad Oldesloe
Ayanda
B Braun
BAG Healthcare
Bankyo Pharmaceuticals
Banner
Bausch & Lomb
Baxter Biopharma Solutions
Bayer Contract Manufacturing
Bell-More
Best Formulations
BI Bioexcellence
BI Contract Manufacturing
Bioluz
BlisFarma
Bluepharma
BMP, bulk medicines & pharmaceuticals production gmbh
BOLDER Arzneimittel GmbH
Boots Contract Manufacturing
Bristol Myers Contract Manufacturing
BSP Pharmaceuticals
Bushu Pharmaceuticals
Cangene bioPharma
Catalent Pharma Solutions
Cenexi
Chanelle Medical
Chartwell
CMIC
Coating Place
Conforma
Cook Pharmica
Corden Pharma
Cosmo Pharmaceuticals
CPL Contract Pharmaceuticals
Custom Pharmaceuticals
Daito
Dechra Pharmaceuticals
Delpharm
Diamond Animal Health
DPT Laboratories
Dr. R. Pfleger
Dr. Reddy’s
DSM Pharmaceuticals
Ei Inc.
E-Pharma Trento
Erfa
Europhartech
Exemplar
Famar
FAREVA Holdings
Fertin Pharma
Fine Foods NTM Spa
Fresenius Kabi
G&W Laboratories, Inc.
GI Pharma
Glatt Pharmaceutical Services
Glaxomithkline
GP Pharmaceutical
Groupe Panpharma
Grunenthal
Halo Pharmaceuticals
Hameln
Hanford
Hasco Lek
Haupt
Helsinn
Hermes Arzneimittel GmbH
Holopack
Hospira
Italfarmaco
Jelfa Pharmaceutical
JHP Pharmaceuticals
Jubilant HollisterStier
26
Contract Dose Manufacturing Industry by the Numbers
©2013 PharmSource • Client Confidential
Kemwell
Klocke Group (inc. IDT)
Kokando
Labiana
Laboratoire AJC
Laboratoire Confab
Laboratoire Elaiapharm
Laboratoires Chemineau
Laboratoires Galéniques Vernin (LGV)
Laboratoires Lavoiser Chaix
Laboratoires Macors/Opodex
Laboratoires Renaudin
Laboratoria Smeets
Laboratoria Wolfs
Lamp San Prospero SPA
Laphal Industrie
Lichtenheldt
Lindopharm
Lomapharm
LTS Lohmann Therapie-Systeme GmbH
Lyophilization Services of New Engalnd
Mayne Pharma
MEDA Manufacturing
Medicofarma SA
Medinsa
Mikart
MIPHARM
Montefarmaco
Nagase Medicals
Neos Therapeutics
Nexgen Pharma
NextPharma
Nipro Pharma
Nitto Medic
Norwich Pharmaceuticals
Nycomed/Takeda
Oakwood Laboratories
Oncotec
Orion Pharma
Orofino Pharmaceuticals Group
Oso Biopharmaceutical
Patheon
Pegasus Labs
Penn Pharmaceutical Services
Pernix Manufacturing
Perrigo/Wrafton
Pfizer CentreSource
Pharma Tech Industries
Pharmaceutics International
Pharmalucence
Pharmapack
Pharmasol/Pharmaserve
Pharmatis
Pierre Fabre
Pierrel
Pillar5 Pharma
Piramal Pharma Solutions
PMRS
Polpharma
Procaps
Purna Pharma
Pyramid Laboratories
Rechon Life Sciences
Recipharm
Reig Jofre
Rentschler
Rottendorf
Rovi Contract Manufacturing
Sandoz
Sanico NV.
Sanochemia
Sanofi CEPIA
Sciarra Laboratories
Siegfried
Sirton
Solupharm
Sovereign Pharmaceuticals
Stason
Sterop Laboratories
Surepharm
Synerlab
Tapemark
Temmler Pharma
Teva Pharmachemie
Thepenier Pharma Industrie S.A.
Toa Pharmaceuticals Co. Ltd
Toll Pharma
Tolmar
“Tower Laboratories, Ltd”
Trillium Health Care Products Inc.
Uman Pharma Inc.
Unicep
Unither
Ursapharm
Valpharma
Vetter Pharma
Vifor Pharma
Wagener & Co. GmbH
Weimer Pharma
WellSpring Pharmaceutical
Wiewelhove
Wockhardt Contract Manufacturing